Atul Dandekar, Chief Strategy and Business Officer of Maze Therapeutics, Inc. (NASDAQ:MAZE), filed a Form 4 on September 4, 2026, disclosing the sale of Common Stock on September 2 and September 3, 2026, to satisfy tax withholding obligations related to the vesting of restricted stock units.

Key Highlights

  • Role: Atul Dandekar is identified as CSBO (Chief Strategy and Business Officer) of Maze Therapeutics, Inc.
  • September 2 sales: 2,800 shares sold at a weighted average price of $26.376 per share, and 391 shares sold at a weighted average price of $27.1211 per share.
  • September 3 sales: 3,207 shares sold at a weighted average price of $26.0133 per share, and 36 shares sold at $25.81 per share.
  • Total shares sold: 6,434 shares across both days, all coded as disposals (D) via transaction code S.
  • Remaining ownership: Following all reported transactions, Dandekar directly owned 32,316 shares of Common Stock.
  • Purpose: According to the filing, all sales were made "to satisfy tax withholding obligations incurred in connection with the vesting of restricted stock units."

Dandekar RSU Vesting Triggers Tax-Related Share Sales at Maze Therapeutics

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Atul Dandekar, the CSBO of Maze Therapeutics, Inc., executed four separate open-market sale transactions across two trading days. The filing states that each reported transaction represents shares sold specifically to cover tax withholding obligations arising from restricted stock unit vesting, not discretionary open-market sales.

On September 2, 2026, the filing reports two disposals: 2,800 shares at a weighted average price of $26.376 (with individual transaction prices ranging from $26.03 to $27.00 per share), and 391 shares at a weighted average price of $27.1211 (ranging from $27.055 to $27.40 per share). Following these two transactions, Dandekar held 35,559 shares directly.

On September 3, 2026, two additional disposals occurred: 3,207 shares at a weighted average price of $26.0133 (ranging from $25.743 to $26.65 per share), and 36 shares at $25.81 per share. After all four transactions, the filing reports Dandekar's direct beneficial ownership at 32,316 shares of Common Stock. The filing was signed by Courtney Phillips as attorney-in-fact on September 4, 2026. No derivative securities transactions were reported.

What Was Disclosed

Atul Dandekar, CSBO of Maze Therapeutics, Inc. (NASDAQ:MAZE), disclosed the sale of 6,434 total shares of Common Stock on September 2-3, 2026, at weighted average prices between $25.81 and $27.1211 per share, all attributed to tax withholding on vested restricted stock units, leaving him with 32,316 shares directly owned.